Report Sections

See All Reports

Coronavirus Infections (840) Severe Acute Respiratory Syndrome (575) Infection (491) Pneumonia (381) Communicable Diseases (217) Respiratory Distress Syndrome, Adult (187) Acute Lung Injury (148) Respiratory Distress Syndrome, Newborn (148) (134) Syndrome (129) Virus Diseases (98) Depression (92) Pneumonia, Viral (81) Critical Illness (69) Anxiety Disorders (57) Neoplasms (47) Respiratory Tract Infections (46) Disease (41) Diabetes Mellitus (39) Cardiovascular Diseases (38) Stress Disorders, Post-Traumatic (38) Emergencies (36) Wounds and Injuries (36) Depressive Disorder (35) Inflammation (35) Lung Diseases (33) Stress Disorders, Traumatic (33) Stress, Psychological (33) Respiratory Tract Diseases (31) Hypoxia (30) Lung Injury (30) Acute Kidney Injury (29) Mental Disorders (29) Thrombosis (29) Influenza, Human (27) Hypertension (25) Respiration Disorders (23) Disease Progression (22) Fibrosis (22) Cognitive Dysfunction (21) Olfaction Disorders (21) Arthritis (20) Diabetes Mellitus, Type 2 (20) Sclerosis (20) Burnout, Psychological (19) Multiple Sclerosis (19) Pulmonary Disease, Chronic Obstructive (19) Respiratory Aspiration (19) Thromboembolism (19) Embolism (18) Lung Diseases, Obstructive (18) Pulmonary Fibrosis (18) HIV Infections (17) Kidney Diseases (17) Stroke (17) Blood Coagulation Disorders (16) Heart Failure (16) Hemostatic Disorders (16) Pulmonary Embolism (16) Arthritis, Rheumatoid (15) Asthma (15) Chronic Disease (15) Heart Diseases (15) Lung Diseases, Interstitial (15) Lung Neoplasms (15) Myocardial Infarction (15) Substance-Related Disorders (15) Autism Spectrum Disorder (14) Chronic Pain (14) Crohn Disease (14) Brain Injuries (13) Diabetes Mellitus, Type 1 (13) Infarction (13) Venous Thrombosis (12) Autistic Disorder (11) Carcinoma (11) Colitis (11) Colitis, Ulcerative (11) Dyspnea (11) Feeding and Eating Disorders (11) Obesity (11) Rheumatic Diseases (11) Ulcer (11) Alzheimer Disease (10) Burnout, Professional (10) Leukemia (10) Lymphoma (10) Myocarditis (10) Overweight (10) Parkinson Disease (10) Pregnancy Complications (10) Renal Insufficiency, Chronic (10) Respiratory Syncytial Virus Infections (10) Sepsis (10) Brain Injuries, Traumatic (9) Collagen Diseases (9) Coronary Artery Disease (9) Cystic Fibrosis (9) Dementia (9) Depression, Postpartum (9) Frailty (9) Inflammatory Bowel Diseases (9) Liver Diseases (9) Musculoskeletal Pain (9) Pneumonia, Ventilator-Associated (9) Pulmonary Valve Insufficiency (9) Renal Insufficiency (9) Venous Thromboembolism (9) Vitamin D Deficiency (9) Weight Loss (9) Alcohol Drinking (8) Alcoholism (8) Hematologic Neoplasms (8) Infertility (8) Ischemia (8) Parasomnias (8) Problem Behavior (8) Psychotic Disorders (8) RNA Virus Infections (8) Breast Neoplasms (7) Convalescence (7) Coronary Disease (7) Dyssomnias (7) Fatigue (7) Metabolic Syndrome (7) Migraine Disorders (7) Myocardial Ischemia (7) Neoplasm Metastasis (7) Psoriasis (7) Schizophrenia (7) Shock (7) Spinal Cord Injuries (7) Toxemia (7) Acute Coronary Syndrome (6) Brain Diseases (6) Bronchiectasis (6) Carcinoma, Non-Small-Cell Lung (6) Child Development Disorders, Pervasive (6) Colorectal Neoplasms (6) Deglutition Disorders (6) Delirium (6) Disease Susceptibility (6) Immune System Diseases (6) Immunologic Deficiency Syndromes (6) Kidney Failure, Chronic (6) Lupus Erythematosus, Systemic (6) Lymphopenia (6) Multiple Organ Failure (6) Neurologic Manifestations (6) Osteoarthritis (6) (6) Pediatric Obesity (6) Prostatic Neoplasms (6) Sleep Apnea Syndromes (6) Sleep Apnea, Obstructive (6) Appendicitis (5) Arthritis, Psoriatic (5) Autoimmune Diseases (5) Coronaviridae Infections (5) Cross Infection (5) Depressive Disorder, Major (5) Dermatitis (5) Disseminated Intravascular Coagulation (5) Fibromyalgia (5) Gastroparesis (5) Head and Neck Neoplasms (5) Hypersensitivity (5) Idiopathic Pulmonary Fibrosis (5) Leukemia, Lymphoid (5) Metabolic Diseases (5) Mobility Limitation (5) Nervous System Diseases (5) Occupational Stress (5) Osteoarthritis, Knee (5) Pancreatic Neoplasms (5) Premature Birth (5) Triple Negative Breast Neoplasms (5) Acquired Immunodeficiency Syndrome (4) Acute Disease (4) Adenoviridae Infections (4) Amyotrophic Lateral Sclerosis (4) Anemia, Sickle Cell (4) Arrhythmias, Cardiac (4) Asymptomatic Diseases (4) Atrial Fibrillation (4) Attention Deficit Disorder with Hyperactivity (4) Behavior, Addictive (4) Body Weight (4) Carcinoma, Renal Cell (4) Cognition Disorders (4) Coinfection (4) Colonic Neoplasms (4) Death (4) Dermatitis, Atopic (4) Digestive System Diseases (4) Eczema (4) Embolism and Thrombosis (4) Endometriosis (4) Gastrointestinal Diseases (4) Headache (4) Heart Arrest (4) Hematologic Diseases (4) Hemophilia A (4) Hemorrhage (4) Hypertension, Pulmonary (4) Intestinal Diseases (4) Liver Cirrhosis (4) Macular Degeneration (4) Malnutrition (4) Motor Neuron Disease (4) (4) Mycobacterium Infections (4) Panic Disorder (4) Peripheral Arterial Disease (4) Postoperative Complications (4) Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) Prediabetic State (4) Signs and Symptoms, Respiratory (4) Sjogren's Syndrome (4) Sleep Initiation and Maintenance Disorders (4) Spondylarthritis (4) Systemic Inflammatory Response Syndrome (4) Thrombophilia (4) Tobacco Use Disorder (4) Vascular Diseases (4) Ventricular Dysfunction (4) Ventricular Dysfunction, Left (4) Apnea (3) Bacteremia (3) Bacterial Infections (3) Bulimia (3) Cardiomyopathies (3) Celiac Disease (3) Cerebral Palsy (3) Chilblains (3) Common Cold (3) Congenital Abnormalities (3) Developmental Disabilities (3) Dysgeusia (3) Endocrine System Diseases (3) Eye Diseases (3) Fatigue Syndrome, Chronic (3) Fatty Liver (3) Fever (3) Fistula (3) Fractures, Bone (3) Ganglion Cysts (3) Giant Cell Arteritis (3) Glucose Intolerance (3) Glucose Metabolism Disorders (3) Heart Defects, Congenital (3) Hepatitis C (3) Huntington Disease (3) Hyperglycemia (3) Hypothermia (3) Kidney Calculi (3) Leukemia, Lymphocytic, Chronic, B-Cell (3) Leukemia, Myeloid, Acute (3) Macular Edema (3) Measles (3) Melanoma (3) Meningitis (3) Mouth Diseases (3) Mucocutaneous Lymph Node Syndrome (3) Multiple Myeloma (3) Multiple Sclerosis, Relapsing-Remitting (3) Myelodysplastic Syndromes (3) Myeloproliferative Disorders (3) Neoplasms, Plasma Cell (3) Neuroendocrine Tumors (3) Non-alcoholic Fatty Liver Disease (3) Obesity, Morbid (3) Obstetric Labor, Premature (3) Ovarian Neoplasms (3) Paramyxoviridae Infections (3) Peripheral Nervous System Diseases (3) Peripheral Vascular Diseases (3) Polymyalgia Rheumatica (3) Pregnancy Complications, Infectious (3) Psychological Trauma (3) Pulmonary Edema (3) Rare Diseases (3) Rheumatic Fever (3) ST Elevation Myocardial Infarction (3) Seizures (3) Shock, Septic (3) Sleep Wake Disorders (3) Small Cell Lung Carcinoma (3) Suicidal Ideation (3) Tachycardia (3) Taste Disorders (3) Tuberculosis (3) Ageusia (2) Agoraphobia (2) Alcoholic Intoxication (2) Alopecia (2) Alpha 1-Antitrypsin Deficiency (2) Angina Pectoris (2) Anxiety, Separation (2) Aortic Valve Stenosis (2) Arteritis (2) Asymptomatic Infections (2) Atherosclerosis (2) Atrophy (2) Back Pain (2) Behcet Syndrome (2) Binge-Eating Disorder (2) Bipolar Disorder (2) Bronchitis (2) Bronchitis, Chronic (2) Bronchopulmonary Dysplasia (2) Caliciviridae Infections (2) Carcinoma, Small Cell (2) Carcinoma, Squamous Cell (2) Cataract (2) Cholangitis (2) Clinical Deterioration (2) Clostridium Infections (2) Communicable Diseases, Emerging (2) Communication Disorders (2) Compassion Fatigue (2) Compulsive Personality Disorder (2) Conjunctivitis (2) Depressive Disorder, Treatment-Resistant (2) Diabetic Nephropathies (2) Diabetic Neuropathies (2) Diarrhea (2) Drug-Related Side Effects and Adverse Reactions (2) Emphysema (2) Endocarditis (2) Epilepsy (2) Facies (2) Fractures, Stress (2) Gastroenteritis (2) Gastroesophageal Reflux (2) Genetic Predisposition to Disease (2) Glioblastoma (2) Gout (2) Healthcare-Associated Pneumonia (2) Heart Failure, Systolic (2) Hepatitis (2) Hepatitis A (2) Humeral Fractures (2) Hyperkinesis (2) Hyperphagia (2) Hyperplasia (2) Hypertension, Pregnancy-Induced (2) Hypotension (2) Hypoventilation (2) Infertility, Male (2) Intervertebral Disc Degeneration (2) Ischemic Attack, Transient (2) Jaundice (2) Joint Diseases (2) Leukemia, Myeloid (2) Low Back Pain (2) Lymphedema (2) Lymphoma, B-Cell (2) Lymphoma, Mantle-Cell (2) Lymphoproliferative Disorders (2) Meningitis, Meningococcal (2) Mood Disorders (2) Mucositis (2) Muscle Spasticity (2) Muscular Dystrophies (2) Mutism (2) Mycoses (2) Myofascial Pain Syndromes (2) Myositis (2) Necrosis (2) Nephrolithiasis (2) Nerve Degeneration (2) Neurocognitive Disorders (2) Neurodevelopmental Disorders (2) Nidovirales Infections (2) Noncommunicable Diseases (2) Nutrition Disorders (2) Obsessive-Compulsive Disorder (2) Oral Manifestations (2) Oropharyngeal Neoplasms (2) Pain (2) Pain, Postoperative (2) Pancreatitis (2) Paresis (2) Periodontal Diseases (2) Phobia, Social (2) Phobic Disorders (2) Pneumonia, Bacterial (2) Pneumonia, Pneumocystis (2) Pre-Eclampsia (2) Preleukemia (2) Pulmonary Eosinophilia (2) Purpura, Thrombocytopenic, Idiopathic (2) Recurrence (2) Respiratory Sounds (2) Rupture (2) Sarcoidosis (2) Sarcopenia (2) (2) Scleroderma, Systemic (2) Spinal Diseases (2) Sprains and Strains (2) Squamous Cell Carcinoma of Head and Neck (2) Stillbirth (2) Stomatitis (2) Suicide (2) Temporomandibular Joint Disorders (2) Temporomandibular Joint Dysfunction Syndrome (2) Thoracic Diseases (2) Thrombocytopenia (2) Thyroid Diseases (2) Trauma and Stressor Related Disorders (2) Urinary Bladder, Overactive (2) Urinary Tract Infections (2) Uterine Cervical Neoplasms (2) Uveitis (2) Vision Disorders (2) Vision, Low (2) Wet Macular Degeneration (2) Yellow Fever (2) Abortion, Spontaneous (1) Abruptio Placentae (1) Acalculous Cholecystitis (1) (1) Adenocarcinoma (1) Adjustment Disorders (1) Adrenal Insufficiency (1) Aggression (1) Alcohol Drinking in College (1) Alcohol-Related Disorders (1) Altitude Sickness (1) Alveolitis, Extrinsic Allergic (1) Amblyopia (1) Anemia (1) Anemia, Aplastic (1) Anemia, Iron-Deficiency (1) Aneurysm (1) Aneurysm, Ruptured (1) Angina, Stable (1) Angioedema (1) Angioedemas, Hereditary (1) Ankle Fractures (1) Anorexia (1) Anorexia Nervosa (1) Arachnoiditis (1) Arthritis, Juvenile (1) Aspergillosis (1) Aspergillosis, Allergic Bronchopulmonary (1) Asphyxia Neonatorum (1) Asthenopia (1) Atrioventricular Block (1) Autonomic Nervous System Diseases (1) Barotrauma (1) Biliary Tract Neoplasms (1) Birth Weight (1) Blister (1) Body Weight Changes (1) Bone Diseases, Metabolic (1) Bone Marrow Diseases (1) Bradycardia (1) Brain Concussion (1) Brain Neoplasms (1) Breast Cancer Lymphedema (1) Bronchial Diseases (1) Bronchiolitis (1) Brucellosis (1) Bruxism (1) Bulimia Nervosa (1) (1) Calculi (1) Carcinoma in Situ (1) Carcinoma, Ductal (1) Carcinoma, Ductal, Breast (1) Carcinoma, Hepatocellular (1) Carcinoma, Intraductal, Noninfiltrating (1) Carcinoma, Ovarian Epithelial (1) Cardiotoxicity (1) Cardiovascular Abnormalities (1) Cellulitis (1) Cerebral Hemorrhage (1) Cerebrovascular Disorders (1) Chest Pain (1) Chlamydia Infections (1) Cholangiocarcinoma (1) Cholangitis, Sclerosing (1) Cholecystitis (1) Cholecystitis, Acute (1) Chorea (1) Chronic Traumatic Encephalopathy (1) Ciliary Motility Disorders (1) Colitis, Ulcerativ (1) Colonic Diseases (1) (1) Compulsive Behavior (1) Consciousness Disorders (1) Constipation (1) Constriction, Pathologic (1) Conversion Disorder (1) (1) Coronary Restenosis (1) Coronary Stenosis (1) (1) Coronavirus Infect (1) Cough (1) Coxsackievirus Infections (1) Crohn Dise (1) Cryopyrin-Associated Periodic Syndromes (1) Deafness (1) Death, Sudden, Cardiac (1) Dehydration (1) Dental Calculus (1) Dental Plaque (1) DiGeorge Syndrome (1) Diabetic Foot (1) Digestive System Neoplasms (1) Diphtheria (1) Down Syndrome (1) Drug Overdose (1) Dry Eye Syndromes (1) Dysentery, Bacillary (1) Dyskinesias (1) Dyspareunia (1) Dysphonia (1) Eclampsia (1) Emergence Delirium (1) Encephalitis (1) Endophthalmitis (1) Endotoxemia (1) Enterocolitis (1) Enterocolitis, Pseudomembranous (1) Enuresis (1) Eosinophilic Esophagitis (1) Epstein-Barr Virus Infections (1) Escherichia coli Infections (1) Esophageal Fistula (1) Esophageal and Gastric Varices (1) Esophagitis (1) Esophagitis, Peptic (1) Eye Infections (1) Fabry Disease (1) Facial Pain (1) Familial Mediterranean Fever (1) Femoral Fractures (1) Femoral Neck Fractures (1) Fetal Growth Retardation (1) Fetal Membranes, Premature Rupture (1) Fever of Unknown Origin (1) Food Hypersensitivity (1) Foot Ulcer (1) Fractures, Closed (1) Gait Disorders, Neurologic (1) Gambling (1) Gastrointestinal Stromal Tumors (1) Gaucher Disease (1) Genetic Diseases, Inborn (1) Geographic Atrophy (1) Gestational Weight Gain (1) Gingivitis, Necrotizing Ulcerative (1) Glomerulonephritis, IGA (1) Glomerulonephritis, Membranous (1) Guillain-Barre Syndrome (1) Halitosis (1) Headache Disorders, Secondary (1) Hearing Loss (1) Hearing Loss, Conductive (1) Heart Block (1) Heart Failure, Diastolic (1) Heart Murmurs (1) Helminthiasis (1) Hematoma (1) Hematoma, Subdural (1) Hematoma, Subdural, Chronic (1) Hemoglobinopathies (1) Hepatitis B (1) Hepatitis, Alcoholic (1) Hereditary Autoinflammatory Diseases (1) Herpes Labialis (1) Herpes Zoster (1) Hoarseness (1) Hodgkin Disease (1) Hot Flashes (1) Hyaline Membrane Disease (1) Hyperaldosteronism (1) Hypercapnia (1) Hyperkalemia (1) Hyperphosphatemia (1) Hypersensitivity, Immediate (1) Hypertrophy (1) Hypokalemia (1) Hyponatremia (1) Hypoparathyroidism (1) Iatrogenic Disease (1) (1) Infant, Newborn, Diseases (1) (1) Infec (1) Infecti (1) Infectious Mononucleosis (1) Infertility, Female (1) Intellectual Disability (1) Intermittent Claudication (1) Intestinal Atresia (1) Intracranial Aneurysm (1) Intracranial Hypertension (1) Intracranial Thrombosis (1) Jaundice, Obstructive (1) Keratoconjunctivitis (1) Keratoconjunctivitis Sicca (1) Keratosis (1) Keratosis, Actinic (1) Language Disorders (1) Leishmaniasis (1) Leukemia, Myelomonocytic, Acute (1) Leukemia, Myelomonocytic, Chronic (1) Leukemia, Prolymphocytic (1) Leukemia, Prolymphocytic, T-Cell (1) Lichen Sclerosus et Atrophicus (1) Liver Cirrhosis, Biliary (1) Liver Failure (1) Lung Ne (1) Lyme Disease (1) Lymphocytosis (1) Lymphoma, Large B-Cell, Diffuse (1) Lymphoma, Non-Hodgkin (1) Macrophage Activation Syndrome (1) Malaria (1) Maternal Death (1) Maxillofacial Injuries (1) May-Thurner Syndrome (1) Memory Disorders (1) Meningococcal Infections (1) Meningomyelocele (1) Menorrhagia (1) Menstruation Disturbances (1) Metabolism, Inborn Errors (1) Microvascular Rarefaction (1) Mitochondrial Diseases (1) Molluscum Contagiosum (1) Monoclonal Gammopathy of Undetermined Significance (1) Mouth, Edentulous (1) Movement Disorders (1) Multiple Chronic Conditions (1) Muscular Atrophy (1) Muscular Dystrophy, Duchenne (1) Myalgia (1) Myelodysplastic-Myeloproliferative Diseases (1) Myocardial Reperfusion Injury (1) Nasal Polyps (1) Needlestick Injuries (1) Neonatal Sepsis (1) Neoplasms, Germ Cell and Embryonal (1) Neoplastic Cells, Circulating (1) Nephritis (1) Nervous System Malformations (1) Neurobehavioral Manifestations (1) Neuromuscular Diseases (1) Neuromyelitis Optica (1) Obsessive Behavior (1) Olfactory Nerve Injuries (1) Oligospermia (1) Opioid-Related Disorders (1) Orbital Cellulitis (1) Osteoarthritis, Hip (1) Osteochondritis (1) Osteomyelitis (1) Otitis (1) Otitis Media (1) Otitis Media with Effusion (1) Overwei (1) Pain, Intractable (1) Pain, Procedural (1) Papillomavirus Infections (1) Paraproteinemias (1) Parkin (1) Peanut Hypersensitivity (1) Perinatal Death (1) Periodontal Pocket (1) Peritoneal Neoplasms (1) Pharyngeal Diseases (1) Pneumon (1) Polyps (1) Pregnancy in Diabetics (1) Presbyopia (1) Primary Dysautonomias (1) Primary Myelofibrosis (1) Prostatic Hyperplasia (1) Protein Deficiency (1) Protein-Energy Malnutrition (1) Pseudomonas Infections (1) Psychophysiologic Disorders (1) Puerperal Infection (1) Pulmonary Alveolar Proteinosis (1) Pulmonary Aspergillosis (1) Pulmonary Atelectasis (1) Pulmonary Heart Disease (1) Rabies (1) Radiculopathy (1) Rectal Fistula (1) Rectal Neoplasms (1) Reperfusion Injury (1) Resp (1) Respiratory Distre (1) Respiratory Distress Sy (1) Respiratory Hypersensitivity (1) Restless Legs Syndrome (1) Retinal Vein Occlusion (1) Rhinitis (1) Rhinitis, Allergic (1) Rhinitis, Allergic, Seasonal (1) Sarcoma (1) Schizophrenia Spectrum and Other Psychotic Disorders (1) Scleroderma, Localized (1) (1) Self-Injurious Behavior (1) Sexually Transmitted Diseases (1) Sexually Transmitted Diseases, Bacterial (1) Shock, Cardiogenic (1) Short Bowel Syndrome (1) Shoulder Fractures (1) Signs and Symptoms, Digestive (1) Skin Abnormalities (1) Skin Diseases (1) Skin Manifestations (1) Skin Neoplasms (1) Skull Fractures (1) Sleep Apnea, Central (1) Soft Tissue Neoplasms (1) Somatoform Disorders (1) Speech Sound Disorder (1) Spina Bifida Cystica (1) Spinal Cord Diseases (1) Spinal Dysraphism (1) Spinal Stenosis (1) Spondylitis (1) Spondylitis, Ankylosing (1) Spondylolisthesis (1) Status Epilepticus (1) Stress Disorders, Traumatic, Acute (1) Subarachnoid Hemorrhage (1) Superinfection (1) Syncope (1) Syncope, Vasovagal (1) Synovial Cyst (1) Tachycardia, Sinus (1) Tachycardia, Supraventricular (1) Tachycardia, Ventricular (1) Tachypnea (1) Thalassemia (1) Thrombophlebitis (1) Thrombotic Microangiopathies (1) Tissue Adhesions (1) Tonsillitis (1) Torsades de Pointes (1) Tourette Syndrome (1) Trauma, Nervous System (1) Trichuriasis (1) Tuberculosis, Meningeal (1) Tuberculosis, Pulmonary (1) Urinary Bladder Neoplasms (1) Urinary Bladder, Underactive (1) Urinary Incontinence (1) Urinary Retention (1) Urogenital Neoplasms (1) Urologic Diseases (1) Urticaria (1) Uterine Neoplasms (1) Vaginal Neoplasms (1) Venous Insufficiency (1) Ventricular Dysfunction, Right (1) Virus (1) Vitamin D Deficie (1) Voice Disorders (1) Von Willebrand Diseases (1) Vulvar Lichen Sclerosus (1) Vulvar Neoplasms (1) Waldenstrom Macroglobulinemia (1) Weight Gain (1) Xerostomia (1) beta-Thalassemia (1)

D001424: Bacterial Infections

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Navigate: Clinical Trials and HPO


Correlated Drug Terms (12)


Name (Synonyms) Correlation
drug3669 Respiratory infections Wiki 0.58
drug1711 Fosfomycin disodium Wiki 0.58
drug993 Cimetidine Wiki 0.58
Name (Synonyms) Correlation
drug3259 Placebo matching to gepotidacin Wiki 0.58
drug875 CVnCoV Wiki 0.58
drug1332 Digoxin Wiki 0.58
drug1783 Gepotidacin Wiki 0.58
drug3693 Rifampicin Wiki 0.41
drug866 CT-Scan Wiki 0.41
drug2615 Midazolam Wiki 0.26
drug895 Camostat Wiki 0.26
drug3195 Placebo Wiki 0.05

Correlated MeSH Terms (9)


Name (Synonyms) Correlation
D012327 RNA Virus Infections NIH 0.20
D018450 Disease Progression NIH 0.12
D007251 Influenza, Human NIH 0.11
Name (Synonyms) Correlation
D012141 Respiratory Tract Infections NIH 0.09
D003141 Communicable Diseases NIH 0.08
D014777 Virus Diseases NIH 0.06
D007239 Infection NIH 0.05
D045169 Severe Acute Respiratory Syndrome NIH 0.02
D018352 Coronavirus Infections NIH 0.02

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0011947 Respiratory tract infection HPO 0.09

Clinical Trials

Navigate: Correlations   HPO

There are 3 clinical trials


1 A Phase 1 Safety and Intrapulmonary Pharmacokinetics Study of ZTI-01 (Intravenous Fosfomycin Disodium) in Healthy Adult Subjects

This is a Phase 1, open-label, multiple-dose trial conducted at a single center. The treatment period will consist of three 6 g doses (18 g) of ZTI-01 as a 1-hour intravenous (IV) infusion (+10 minute window). A total of 30 enrolled subjects will be randomized to undergo a single standardized bronchoscopy with bronchoalveolar lavage (BAL) at one of five sampling times. A total of 6 subjects will be assigned to each BAL-sampling time. Up to ten additional enrolled subjects will act as alternates to obtain 30 evaluable subjects. An evaluable subject is defined as a subject who receives all doses of ZTI-01, undergoes BAL at the randomized sampling timepoint with BAL return volume adequate for testing, and undergoes at least the one blood sampling timepoint that is concurrent with the assigned BAL sampling timepoint, with blood sampling volume that is adequate for testing. The objectives of the study are to assess safety and pharmacokinetics (PK) for a multiple dose regimen of IV-infused ZTI-01.

NCT03910673
Conditions
  1. Bacterial Infection
  2. Multiple-drug Resistance
  3. Pathogen Resistance
Interventions
  1. Drug: Fosfomycin disodium
MeSH:Bacterial Infections

Primary Outcomes

Description: Concentrations will be measured by a validated LC-MS/MS bioanalytical assay for the blood samples collected during the study.

Measure: Area under the concentration vs. time curve (AUC0-8 and AUC0-infinity) for ZTI -01

Time: Day 1 to Day 2

Description: Concentrations will be measured by a validated LC-MS/MS bioanalytical assay for the blood samples collected during the study

Measure: Clearance (CL) of ZTI-01

Time: Day 1 to Day 2

Description: Defined as percent penetration of lung epithelial lining fluid (ELF) and alveolar macrophages (AMs). The ratios of ELF and AM concentrations of fosfomycin to simultaneous plasma concentrations will be calculated for each subject and summarized for each sampling time. The median concentrations of fosfomycin from the BAL sampling times will be used to estimate the AUC0-8 of plasma, ELF, and AM. The ratio of AUC0-8 of ELF-to-plasma and AM-to-plasma will be calculated to determine the percent penetration.

Measure: Intrapulmonary pharmacokinetics of ZTI-01

Time: Day 1 to Day 2

Description: Concentrations will be measured by a validated LC-MS/MS bioanalytical assay for the blood samples collected during the study.

Measure: Maximum measured plasma concentration (Cmax) of ZTI-01

Time: Day 1 to Day 2

Description: Clinical laboratory evaluations include serum chemistry (albumin, glucose, blood urea nitrogen (BUN), potassium, magnesium, calcium, sodium, total protein, creatinine, triglycerides, total cholesterol, creatine phosphokinase (CPK), phosphorus, alkaline phosphatase (ALP), AST, ALT, total bilirubin, direct bilirubin, and lactate dehydrogenase (LDH)), hematology (CBC with differential (hemoglobin, hematocrit, platelet count, white blood cell (WBC) count, neutrophils, lymphocytes, monocytes, eosinophils, basophils)), coagulation (PT and aPTT), urinalysis (leukocyte esterase, blood, pH, specific gravity, glucose, protein), and plasma urea concentration.

Measure: Number of participants experiencing abnormal clinical laboratory assessments compared to baseline

Time: Day 1 to Day 2

Description: Physical exams will include assessment of skin, head and neck, lungs, heart, liver, spleen, extremities, lymph nodes, musculoskeletal system/extremities, abdomen, nervous system, weight, height, and body mass index (BMI).

Measure: Number of participants experiencing abnormal physical examination findings compared to baseline

Time: Day 1 to Day 2

Description: Vital sign measurements will include heart rate, blood pressure, temperature, respiratory rate, and peripheral oxygen saturation.

Measure: Number of participants experiencing abnormal vital sign measurements compared to baseline

Time: Day 1 to Day 2

Measure: Number of participants experiencing adverse events (AEs)

Time: Day 1 to Day 3

Description: QTc, PR, and QRS intervals are expressed in milliseconds (msec).

Measure: Number of participants with prolonged QTc, PR, or QRS interval in electrocardiogram (ECG) readings

Time: Day 1 to Day 2

Description: Concentrations will be measured by a validated LC-MS/MS bioanalytical assay for the blood samples collected during the study.

Measure: Terminal elimination half-life (t1/2) of ZTI-01

Time: Day 1 to Day 2

Description: Concentrations will be measured by a validated LC-MS/MS bioanalytical assay for the blood samples collected during the study.

Measure: Terminal-phase elimination rate constant (lambdaz) of ZTI-01

Time: Day 1 to Day 2

Description: Concentrations will be measured by a validated LC-MS/MS bioanalytical assay for the blood samples collected during the study.

Measure: Time to peak concentration (Tmax) of ZTI-01

Time: Day 1 to Day 2

Description: Concentrations will be measured by a validated LC-MS/MS bioanalytical assay for the blood samples collected during the study.

Measure: Volume of ZTI-01 distribution (Vd)

Time: Day 1 to Day 2
2 A Pharmacokinetic, Multi-cohort Study in Healthy Adult Subjects to Assess Gepotidacin as Victim and as Perpetrator of Drug-Drug Interactions Via CYP450, Renal and Intestinal Transporters, and to Assess Gepotidacin Pharmacokinetics in Japanese Healthy Adults

This study is a drug-drug interaction (DDI), pharmacokinetics (PK), safety and tolerability study in adult healthy participants, including Japanese cohort. This study is designed to assess co-administration of probe substrates with gepotidacin in study cohorts 1 to 3 and establishing PK and safety in Japanese participants in cohort 4. Food effect will also be evaluated in cohort 4.

NCT04493931
Conditions
  1. Bacterial Infections
  2. Infections, Bacterial
Interventions
  1. Drug: Gepotidacin
  2. Drug: Cimetidine
  3. Drug: Rifampicin
  4. Drug: Midazolam
  5. Drug: Digoxin
  6. Other: Placebo matching to gepotidacin
MeSH:Infection Communicable Diseases Bacterial Infections

Primary Outcomes

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 1: Maximum observed concentration (Cmax) of gepotidacin

Time: Up to 48 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 1: Time to reach maximum observed plasma concentration (Tmax) of gepotidacin

Time: Up to 48 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 1: Terminal phase half-life (t1/2) of gepotidacin

Time: Up to 48 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 1: Area under the concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC [0-t]) of gepotidacin

Time: Up to 48 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 1: AUC from time 0 (predose) extrapolated to infinite time (AUC[0-infinity]) of gepotidacin

Time: Up to 48 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 2: Cmax of gepotidacin

Time: Up to 48 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 2: Lag time before observation of drug concentrations (Tlag) of gepotidacin

Time: Up to 48 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 2: Tmax of gepotidacin

Time: Up to 48 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 2: AUC(0-t) of gepotidacin

Time: Up to 48 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 2: AUC(0-infinity) of gepotidacin

Time: Up to 48 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of digoxin.

Measure: Cohort 3: Cmax of digoxin

Time: Up to 96 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of digoxin.

Measure: Cohort 3: Tlag of digoxin

Time: Up to 96 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of digoxin.

Measure: Cohort 3: Tmax of digoxin

Time: Up to 96 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of digoxin.

Measure: Cohort 3: AUC(0-t) of digoxin

Time: Up to 96 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of digoxin.

Measure: Cohort 3: AUC(0-infinity) of digoxin

Time: Up to 96 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of midazolam.

Measure: Cohort 3: Cmax of midazolam

Time: Up to 48 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of midazolam.

Measure: Cohort 3: Tlag of midazolam

Time: Up to 48 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of midazolam.

Measure: Cohort 3: Tmax of midazolam

Time: Up to 48 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of midazolam.

Measure: Cohort 3: AUC(0-t) of midazolam

Time: Up to 48 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of midazolam.

Measure: Cohort 3: AUC(0-infinity) of midazolam

Time: Up to 48 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: Cmax of gepotidacin after a single 1500 mg dose

Time: Up to 48 hours post dose in Period 1 and Period 2

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: Tmax of gepotidacin after a single 1500 mg dose

Time: Up to 48 hours post dose in Period 1 and Period 2

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: AUC from time 0 (predose) to 24 hours post dose administration (AUC [0-24]) of gepotidacin after a single 1500 mg dose

Time: Up to 24 hours post dose in Period 1 and Period 2

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: AUC from time 0 (predose) to 48 hours post dose administration (AUC [0-48]) of gepotidacin after a single 1500 mg dose

Time: Up to 48 hours post dose in Period 1 and Period 2

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: AUC(0-t) of gepotidacin after a single 1500 mg dose

Time: Up to 48 hours post dose in Period 1 and Period 2

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: AUC(0-infinity) of gepotidacin after a single 1500 mg dose

Time: Up to 48 hours post dose in Period 1 and Period 2

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: Cmax of gepotidacin after the first dose of 3000 mg (morning dose)

Time: Up to 60 hours post morning dose in Period 3

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: Tmax of gepotidacin after the first dose of 3000 mg (morning dose)

Time: Up to 60 hours post morning dose in Period 3

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: AUC from time 0 (predose) to time tau (AUC[0-tau]) of gepotidacin after the first dose of 3000 mg (morning dose)

Time: Up to 60 hours post morning dose in Period 3

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: Cmax of gepotidacin after the second dose of 3000 mg (evening dose)

Time: From start of evening dose up to 48 hours post evening dose in Period 3

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: Tmax of gepotidacin after the second dose of 3000 mg gepotidacin (evening dose)

Time: From start of evening dose up to 48 hours post evening dose in Period 3

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: AUC(0-tau) of gepotidacin after the second dose of 3000 mg (evening dose)

Time: From start of evening dose up to 48 hours post evening dose in Period 3

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: Accumulation ratio for Cmax (RoCmax) of gepotidacin after the second dose of 3000 mg (evening dose)

Time: From start of morning dose up to 48 hours post evening dose in Period 3

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: Accumulation ratio for AUC (RoAUC) of gepotidacin after the second dose of 3000 mg (evening dose)

Time: From start of morning dose up to 48 hours post evening dose in Period 3

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: AUC(0-24) of gepotidacin using the full profile (morning + evening doses) following two 3000 mg doses

Time: From start of morning dose up to 24 hours post morning dose (first dose) in Period 3

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: AUC(0-48) of gepotidacin using the full profile (morning + evening doses) following two 3000 mg doses

Time: From start of morning dose up to 48 hours post morning dose (first dose) in Period 3

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: AUC(0-t) of gepotidacin using the full profile (morning + evening doses) following two 3000 mg doses

Time: From start of morning dose up to 60 hours post morning dose in Period 3

Description: AEs will be collected.

Measure: Cohort 4: Number of participants with non-serious adverse events (non-SAEs)

Time: Up to Day 16

Description: SAEs will be collected.

Measure: Cohort 4: Number of participants with serious adverse events (SAEs)

Time: Up to Day 16

Description: Number of participants with abnormal vital signs will be assessed.

Measure: Cohort 4: Number of participants with abnormal vital signs

Time: Up to Day 16

Description: Single 12-lead ECG will be obtained using an ECG machine. Number of participants with abnormal ECG parameters will be assessed.

Measure: Cohort 4: Number of participants with abnormal electrocardiogram (ECG) findings

Time: Up to Day 16

Description: Blood samples will be collected for the assessment of hematology parameters.

Measure: Cohort 4: Number of participants with abnormal hematology parameters

Time: Up to Day 16

Description: Blood samples will be collected for the assessment of chemistry parameters.

Measure: Cohort 4: Number of participants with abnormal clinical chemistry parameters

Time: Up to Day 16

Description: Urine samples will be collected for the assessment of urinalysis parameters.

Measure: Cohort 4: Number of participants with abnormal urinalysis findings

Time: Up to Day 16

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: Cmax of gepotidacin after a single 1500 mg dose under fed conditions

Time: Up to 48 hours post dose in Period 1 and Period 2

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: Tlag of gepotidacin after a single 1500 mg dose under fed conditions

Time: Up to 48 hours post dose in Period 1 and Period 2

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: Tmax of gepotidacin after a single 1500 mg dose under fed conditions

Time: Up to 48 hours post dose in Period 1 and Period 2

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: AUC(0-t) of gepotidacin after a single 1500 mg dose under fed conditions

Time: Up to 48 hours post dose in Period 1 and Period 2

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: AUC(0-infinity) of gepotidacin after a single 1500 mg dose under fed conditions

Time: Up to 48 hours post dose in Period 1 and Period 2

Secondary Outcomes

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 1: AUC(0-24) of gepotidacin

Time: Up to 24 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 1: AUC(0-48) of gepotidacin

Time: Up to 48 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 1: Tlag of a gepotidacin

Time: Up to 48 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 1: Apparent volume of distribution (Vz/F) of gepotidacin

Time: Up to 48 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 1: Apparent oral clearance (CL/F) of gepotidacin

Time: Up to 48 hours post dose in each period

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 1: Total unchanged drug (Ae total) of gepotidacin in urine

Time: Up to 48 hours post dose in each period

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 1: AUC(0-24) of gepotidacin in urine

Time: Up to 24 hours post dose in each period

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 1: AUC(0-48) of gepotidacin in urine

Time: Up to 48 hours post dose in each period

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 1: Renal clearance of drug (CLr) of gepotidacin

Time: Up to 48 hours post dose in each period

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 1: Amount of drug excreted in urine in a time interval (Ae[t1-t2]) of gepotidacin

Time: Up to 48 hours post dose in each period

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 1: Percentage of the given dose of drug excreted in urine (fe%) of gepotidacin

Time: Up to 48 hours post dose in each period

Description: AEs will be collected.

Measure: Cohort 1: Number of participants with non-SAEs

Time: Up to Day 14

Description: SAEs will be collected.

Measure: Cohort 1: Number of participants with SAEs

Time: Up to Day 14

Description: Blood samples will be collected for the assessment of hematology parameters.

Measure: Cohort 1: Number of participants with abnormal hematology parameters

Time: Up to Day 14

Description: Blood samples will be collected for the assessment of chemistry parameters.

Measure: Cohort 1: Number of participants with abnormal clinical chemistry parameters

Time: Up to Day 14

Description: Urine samples will be collected for the assessment of urinalysis parameters.

Measure: Cohort 1: Number of participants with abnormal urinalysis findings

Time: Up to Day 14

Description: Number of participants with abnormal vital signs will be assessed.

Measure: Cohort 1: Number of participants with abnormal vital signs

Time: Up to Day 14

Description: Single 12-lead ECG will be obtained using an ECG machine. Number of participants with abnormal ECG parameters will be assessed.

Measure: Cohort 1: Number of participants with abnormal ECG findings

Time: Up to Day 14

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 2: AUC(0-24) of gepotidacin

Time: Up to 24 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 2: AUC(0-48) of gepotidacin

Time: Up to 48 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 2: T1/2 of a gepotidacin

Time: Up to 48 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 2: Vz/F of gepotidacin

Time: Up to 48 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 2: CL/F of gepotidacin

Time: Up to 48 hours post dose in each period

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 2: Ae total of gepotidacin in urine

Time: Up to 48 hours post dose in each period

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 2: AUC(0-24) of gepotidacin in urine

Time: Up to 24 hours post dose in each period

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 2: AUC(0-48) of gepotidacin in urine

Time: Up to 48 hours post dose in each period

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 2: CLr of gepotidacin in urine

Time: Up to 48 hours post dose in each period

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 2: Ae(t1-t2) of gepotidacin in urine

Time: Up to 48 hours post dose in each period

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 2: fe% of gepotidacin in urine

Time: Up to 48 hours post dose in each period

Description: AEs will be collected.

Measure: Cohort 2: Number of participants with non-SAEs

Time: Up to Day 20

Description: SAEs will be collected.

Measure: Cohort 2: Number of participants with SAEs

Time: Up to Day 20

Description: Blood samples will be collected for the assessment of hematology parameters.

Measure: Cohort 2: Number of participants with abnormal hematology parameters

Time: Up to Day 20

Description: Blood samples will be collected for the assessment of chemistry parameters.

Measure: Cohort 2: Number of participants with abnormal clinical chemistry parameters

Time: Up to Day 20

Description: Urine samples will be collected for the assessment of urinalysis parameters.

Measure: Cohort 2: Number of participants with abnormal urinalysis findings

Time: Up to Day 20

Description: Number of participants with abnormal vital signs will be assessed.

Measure: Cohort 2: Number of participants with abnormal vital signs

Time: Up to Day 20

Description: Single 12-lead ECG will be obtained using an ECG machine. Number of participants with abnormal ECG parameters will be assessed.

Measure: Cohort 2: Number of participants with abnormal ECG findings

Time: Up to Day 20

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 3: Cmax of gepotidacin after the first dose of 3000 mg (morning dose)

Time: Up to 60 hours post morning dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 3: Tmax of gepotidacin after the first dose of 3000 mg (morning dose)

Time: Up to 60 hours post morning dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 3: Tlag of gepotidacin after the first dose of 3000 mg (morning dose)

Time: Up to 60 hours post morning dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 3: AUC(0-tau) of gepotidacin first dose of 3000 mg (morning dose)

Time: Up to 60 hours post morning dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 3: Cmax of gepotidacin after the second dose of 3000 mg (evening dose)

Time: From start of evening dose up to 48 hours post evening dose in each Period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 3: Tmax of gepotidacin after the second dose of 3000 mg (evening dose)

Time: From start of evening dose up to 48 hours post evening dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 3: RoCmax of gepotidacin after the second dose of 3000 mg (evening dose)

Time: From start of morning dose up to 48 hours post evening dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 3: RoAUC of gepotidacin after the second dose of 3000 mg (evening dose)

Time: From start of morning dose up to 48 hours post evening dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 3: AUC(0-tau) of gepotidacin after the second dose of 3000 mg (evening dose)

Time: From start of evening dose up to 48 hours post evening dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 3: AUC(0-24) of gepotidacin using the full profile (morning + evening doses) following two 3000 mg doses

Time: From start of morning dose up to 24 hours post morning dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 3: AUC(0-48) of gepotidacin using the full profile (morning + evening doses) following two 3000 mg doses

Time: From start of morning dose up to 48 hours post morning dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 3: AUC(0-t) of gepotidacin using the full profile (morning + evening doses) following two 3000 mg doses

Time: From start of morning dose up to 60 hours post morning dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 3: Vz/Fof gepotidacin using the full profile (morning + evening doses) following two 3000 mg doses

Time: From start of morning dose up to 60 hours post morning dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 3: CL/F of gepotidacin using the full profile (morning + evening doses) following two 3000 mg doses

Time: From start of morning dose up to 60 hours post morning dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 3: T1/2 of gepotidacin using the full profile (morning + evening doses) following two 3000 mg doses

Time: From start of morning dose up to 60 hours post morning dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of digoxin.

Measure: Cohort 3: Trough concentration (Cmin) of digoxin

Time: Up to 96 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of digoxin.

Measure: Cohort 3: t1/2 of digoxin

Time: Up to 96 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of digoxin.

Measure: Cohort 3: Vz/F of digoxin

Time: Up to 96 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of digoxin.

Measure: Cohort 3: CL/F of digoxin

Time: Up to 96 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of midazolam.

Measure: Cohort 3: Cmin of midazolam

Time: Up to 48 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of midazolam.

Measure: Cohort 3: t1/2 of midazolam

Time: Up to 48 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of midazolam.

Measure: Cohort 3: Vz/F of midazolam

Time: Up to 48 hours post dose in each period

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of midazolam.

Measure: Cohort 3: CL/F of midazolam

Time: Up to 48 hours post dose in each period

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 3: Ae total of gepotidacin in urine following two 3000 mg doses

Time: From start of morning dose up to 60 hours post morning dose in each period

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 3: Ae(t1-t2) of gepotidacin in urine following two 3000 mg doses

Time: From start of morning dose up to 60 hours post morning dose in each period

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 3: AUC(0-tau) of gepotidacin in urine following two 3000 mg doses

Time: From start of morning dose up to 60 hours post morning dose in each period

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 3: AUC(0-24) of gepotidacin in urine following two 3000 mg doses

Time: From start of morning dose up to 24 hours post morning dose in each period

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 3: AUC(0-48) of gepotidacin in urine following two 3000 mg doses (urine)

Time: From start of morning dose up to 48 hours post morning dose in each period

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 3: fe% of gepotidacin in urine following two 3000 mg doses

Time: From start of morning dose up to 48 hours post morning dose in each period

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 3: CLr of gepotidacin in urine following two 3000 mg doses

Time: From start of morning dose up to 60 hours post morning dose in each period

Description: AEs will be collected.

Measure: Cohort 3: Number of participants with non-SAEs

Time: Up to Day 30

Description: SAEs will be collected.

Measure: Cohort 3: Number of participants with SAEs

Time: Up to Day 30

Description: Blood samples will be collected for the assessment of hematology parameters.

Measure: Cohort 3: Number of participants with abnormal hematology parameters

Time: Up to Day 30

Description: Blood samples will be collected for the assessment of chemistry parameters.

Measure: Cohort 3: Number of participants with abnormal clinical chemistry parameters

Time: Up to Day 30

Description: Urine samples will be collected for the assessment of urinalysis parameters.

Measure: Cohort 3: Number of participants with abnormal urinalysis

Time: Up to Day 30

Description: Number of participants with abnormal vital signs will be assessed.

Measure: Cohort 3: Number of participants with abnormal vital signs

Time: Up to Day 30

Description: Single 12-lead ECG will be obtained using an ECG machine. Number of participants with abnormal ECG findings will be assessed.

Measure: Cohort 3: Number of participants with abnormal ECG findings

Time: Up to Day 30

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: T1/2 of gepotidacin after a single 1500 mg dose

Time: Up to 48 hours post dose in Period 1 and Period 2

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: Vz/F of gepotidacin after a single 1500 mg dose

Time: Up to 48 hours post dose in Period 1 and Period 2

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: CL/F of gepotidacin after a single 1500 mg dose

Time: Up to 48 hours post dose in Period 1 and Period 2

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: Tlag of gepotidacin after the first dose of 3000 mg (morning dose)

Time: Up to 60 hours post morning dose in Period 3

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: Vz/F of gepotidacin using the full profile (morning + evening doses) following two 3000 mg doses

Time: From start of morning dose up to 60 hours post morning dose in Period 3

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: CL/F of gepotidacin using the full profile (morning + evening doses) following two 3000 mg doses

Time: From start of morning dose up to 60 hours post morning dose in Period 3

Description: Blood samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: t1/2 of gepotidacin using the full profile (morning + evening doses) following two 3000 mg doses

Time: From start of morning dose up to 60 hours post morning dose in Period 3

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: Ae total of gepotidacin in urine after a single 1500 mg dose

Time: Up to 48 hours post dose in Period 1 and Period 2

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: Ae(t1-t2) of gepotidacin in urine after a single 1500 mg dose

Time: Up to 48 hours post dose in Period 1 and Period 2

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: AUC(0-tau) of gepotidacin in urine after a single 1500 mg dose

Time: Up to 48 hours post dose in Period 1 and Period 2

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: AUC(0-24) of gepotidacin in urine after a single 1500 mg dose

Time: Up to 24 hours post dose in Period 1 and Period 2

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: AUC(0-48) of gepotidacin in urine after a single 1500 mg dose

Time: Up to 48 hours post dose in Period 1 and Period 2

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: fe% of gepotidacin in urine after a single 1500 mg dose

Time: Up to 48 hours post dose in Period 1 and Period 2

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: CLr of gepotidacin in urine after a single 1500 mg dose

Time: Up to 48 hours post dose in Period 1 and Period 2

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: Ae total of gepotidacin in urine following two 3000 mg doses

Time: From start of morning dose up to 60 hours post morning dose in Period 3

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: Ae(t1-t2) of gepotidacin in urine following two 3000 mg doses

Time: From start of morning dose up to 60 hours post morning dose in Period 3

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: AUC(0-tau) of gepotidacin in urine following two 3000 mg doses

Time: From start of morning dose up to 60 hours post morning dose in Period 3

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: AUC(0-24) of gepotidacin in urine following two 3000 mg doses

Time: From start of morning dose up to 24 hours post morning dose in Period 3

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: AUC(0-48) of gepotidacin in urine following two 3000 mg doses

Time: From start of morning dose up to 48 hours post morning dose in Period 3

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: fe% of gepotidacin in urine following two 3000 mg doses

Time: From start of morning dose up to 60 hours post morning dose in Period 3

Description: Urine samples will be collected at indicated time points for the pharmacokinetic analysis of gepotidacin.

Measure: Cohort 4: CLr of gepotidacin in urine following two 3000 mg doses

Time: From start of morning dose up to 60 hours post morning dose in Period 3
3 Predicting Severity and Disease Progression in Influenza-like Illness

Respiratory infections such as colds, flu and pneumonia affect millions of people around the world every year. Most cases are mild, but some people become very unwell. Influenza ('flu') is one of the most common causes of lung infection. Seasonal flu affects between 10% and 46% of the population each year and causes around 12 deaths in every 100,000 people infected. In addition, both influenza and coronaviruses have caused pandemics in recent years, leading to severe disease in many people. Although flu vaccines are available, these need to change every year to overcome rapid changes in the virus and are not completely protective. This study aims to find and develop predictive tests to better understand how and when flu-like illness progresses to more severe disease. This may help to decide which people need to be admitted to hospital, and how their treatment needs to be increased or decreased during infection. The aim is to recruit 100 patients admitted to hospital due to a respiratory infection. It is voluntary to take part and participants can choose to withdraw at any time. The study will involve some blood and nose samples. This will be done on Day 0, Day 2 and Discharge from hospital, and an out-patient follow-up visit on Day 28. The data will be used to develop novel diagnostic tools to assist in rational treatment decisions that will benefit both individual patients and resource allocation. It will also establish research preparedness for upcoming pandemics.

NCT04664075
Conditions
  1. Influenza
  2. SARS (Severe Acute Respiratory Syndrome)
  3. Respiratory Viral Infection
  4. Respiratory Tract Infections
  5. Infection, Bacterial
  6. Infection Viral
  7. Covid19
  8. RNA Virus Infections
Interventions
  1. Biological: Respiratory infections
MeSH:Infection Communicable Diseases Respiratory Tract Infections Bacterial Infections Influenza, Human Virus Diseases Severe Acute Respiratory Syndrome Coronavirus Infec Coronavirus Infections RNA Virus Infections Disease Progression
HPO:Respiratory tract infection

Primary Outcomes

Description: The identity of pathological organisms associated with influenza-like illness (including respiratory viruses and bacteria) will be obtained from the patient's medical record

Measure: Describe the aetiology of influenza-like illness in hospitalised adults

Time: Day 0 to Day 28

Description: The following data will be collected from the patient's medical record. At enrolment, data will consist of: past medical history, clinical signs and symptoms relating to this admission, vital signs (pulse rate, blood pressure, temperature, oxygen saturation), demographics, drug history, laboratory results including diagnostic microbiological tests and interventions. Data collection on Day 28 will consist of clinical diagnosis at discharge, any febrile illness in the 7 days preceding the visit, mortality and complications between Day 0 and 28.

Measure: Describe the clinical outcomes of influenza-like illness in hospitalised adults

Time: Day 0 to Day 28

Secondary Outcomes

Description: Cytokine levels will be measured in plasma and nasal lining fluid samples by MesoScale Discovery

Measure: Identify changes in cytokine levels during influenza-like illness in hospitalised adults

Time: Day 0 to Day 28

HPO Nodes


HPO

Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


HPO Nodes


Reports

Data processed on December 13, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports   MeSH Reports   HPO Reports  

Interventions

4,818 reports on interventions/drugs

MeSH

706 reports on MeSH terms

HPO

306 reports on HPO terms

All Terms

Alphabetical index of all Terms

Google Colab

Python example via Google Colab Notebook